Citrate anticoagulation for continuous venovenous hemofiltration

Heleen M. Oudemans-Van Straaten, Rob J. Bosman, Matty Koopmans, Peter H.J. Van Der Voort, Jos P.J. Wester, Johan I. Van Der Spoel, Lea M. Dijksman, Durk F. Zandstra

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

OBJECTIVE:: Continuous venovenous hemofiltration (CVVH) is applied in critically ill patients with acute renal failure for renal replacement. Heparins used to prevent circuit clotting may cause bleeding. Regional anticoagulation with citrate reduces bleeding, but has metabolic risks. The aim was to compare the safety and efficacy of the two. DESIGN:: Randomized, nonblinded, controlled single-center trial. SETTING:: General intensive care unit of a teaching hospital. PATIENTS:: Adult critically ill patients needing CVVH for acute renal failure and without an increased bleeding risk. INTERVENTIONS:: Regional anticoagulation with citrate or systemic anticoagulation with the low-molecular weight heparin nadroparin. MEASUREMENTS AND MAIN RESULTS:: End points were adverse events necessitating discontinuation of study anticoagulant, transfusion, metabolic and clinical outcomes, and circuit survival. Of the 215 randomized patients, 200 received CVVH per protocol (97 citrate and 103 nadroparin). Adverse events required discontinuation of citrate in two patients (accumulation and clotting) of nadroparin in 20 (bleeding and thrombocytopenia) (p < 0.001). Bleeding occurred in 6 vs. 16 patients (p = 0.08). The median number of red blood cell units transfused per CVVH day was 0.27 (interquartile range, 0.0-0.63) for citrate, 0.36 (interquartile range, 0-0.83) for nadroparin (p = 0.31). Citrate conferred less metabolic alkalosis (p = 0.001) and lower plasma calcium (p < 0.001). Circuit survival was similar. Three-month mortality on intention-to-treat was 48% (citrate) and 63% (nadroparin) (p = 0.03), per protocol 45% and 62% (p = 0.02). Citrate reduced mortality in surgical patients (p = 0.007), sepsis (p = 0.01), higher Sepsis-Related Organ Failure Assessment score (p = 0.006), and lower age (p = 0.009). CONCLUSIONS:: The efficacy of citrate and nadroparin anticoagulation for CVVH was similar, however, citrate was safer. Unexpectedly, citrate reduced mortality. Less bleeding could only partly explain this benefit, less clotting could not. Post hoc citrate appeared particularly beneficial after surgery, in sepsis and severe multiple organ failure, suggesting interference with inflammation.

Original languageEnglish
Pages (from-to)545-552
Number of pages8
JournalCritical Care Medicine
Volume37
Issue number2
DOIs
Publication statusPublished - 1 Jan 2009

Cite this

Oudemans-Van Straaten, H. M., Bosman, R. J., Koopmans, M., Van Der Voort, P. H. J., Wester, J. P. J., Van Der Spoel, J. I., ... Zandstra, D. F. (2009). Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine, 37(2), 545-552. https://doi.org/10.1097/CCM.0b013e3181953c5e
Oudemans-Van Straaten, Heleen M. ; Bosman, Rob J. ; Koopmans, Matty ; Van Der Voort, Peter H.J. ; Wester, Jos P.J. ; Van Der Spoel, Johan I. ; Dijksman, Lea M. ; Zandstra, Durk F. / Citrate anticoagulation for continuous venovenous hemofiltration. In: Critical Care Medicine. 2009 ; Vol. 37, No. 2. pp. 545-552.
@article{b60bff690581497db2a68dc398b79f80,
title = "Citrate anticoagulation for continuous venovenous hemofiltration",
abstract = "OBJECTIVE:: Continuous venovenous hemofiltration (CVVH) is applied in critically ill patients with acute renal failure for renal replacement. Heparins used to prevent circuit clotting may cause bleeding. Regional anticoagulation with citrate reduces bleeding, but has metabolic risks. The aim was to compare the safety and efficacy of the two. DESIGN:: Randomized, nonblinded, controlled single-center trial. SETTING:: General intensive care unit of a teaching hospital. PATIENTS:: Adult critically ill patients needing CVVH for acute renal failure and without an increased bleeding risk. INTERVENTIONS:: Regional anticoagulation with citrate or systemic anticoagulation with the low-molecular weight heparin nadroparin. MEASUREMENTS AND MAIN RESULTS:: End points were adverse events necessitating discontinuation of study anticoagulant, transfusion, metabolic and clinical outcomes, and circuit survival. Of the 215 randomized patients, 200 received CVVH per protocol (97 citrate and 103 nadroparin). Adverse events required discontinuation of citrate in two patients (accumulation and clotting) of nadroparin in 20 (bleeding and thrombocytopenia) (p < 0.001). Bleeding occurred in 6 vs. 16 patients (p = 0.08). The median number of red blood cell units transfused per CVVH day was 0.27 (interquartile range, 0.0-0.63) for citrate, 0.36 (interquartile range, 0-0.83) for nadroparin (p = 0.31). Citrate conferred less metabolic alkalosis (p = 0.001) and lower plasma calcium (p < 0.001). Circuit survival was similar. Three-month mortality on intention-to-treat was 48{\%} (citrate) and 63{\%} (nadroparin) (p = 0.03), per protocol 45{\%} and 62{\%} (p = 0.02). Citrate reduced mortality in surgical patients (p = 0.007), sepsis (p = 0.01), higher Sepsis-Related Organ Failure Assessment score (p = 0.006), and lower age (p = 0.009). CONCLUSIONS:: The efficacy of citrate and nadroparin anticoagulation for CVVH was similar, however, citrate was safer. Unexpectedly, citrate reduced mortality. Less bleeding could only partly explain this benefit, less clotting could not. Post hoc citrate appeared particularly beneficial after surgery, in sepsis and severe multiple organ failure, suggesting interference with inflammation.",
keywords = "Acute renal failure, Anticoagulation, Citrate, Hemofiltration, Heparin, Nadroparin, Sepsi",
author = "{Oudemans-Van Straaten}, {Heleen M.} and Bosman, {Rob J.} and Matty Koopmans and {Van Der Voort}, {Peter H.J.} and Wester, {Jos P.J.} and {Van Der Spoel}, {Johan I.} and Dijksman, {Lea M.} and Zandstra, {Durk F.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1097/CCM.0b013e3181953c5e",
language = "English",
volume = "37",
pages = "545--552",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Oudemans-Van Straaten, HM, Bosman, RJ, Koopmans, M, Van Der Voort, PHJ, Wester, JPJ, Van Der Spoel, JI, Dijksman, LM & Zandstra, DF 2009, 'Citrate anticoagulation for continuous venovenous hemofiltration' Critical Care Medicine, vol. 37, no. 2, pp. 545-552. https://doi.org/10.1097/CCM.0b013e3181953c5e

Citrate anticoagulation for continuous venovenous hemofiltration. / Oudemans-Van Straaten, Heleen M.; Bosman, Rob J.; Koopmans, Matty; Van Der Voort, Peter H.J.; Wester, Jos P.J.; Van Der Spoel, Johan I.; Dijksman, Lea M.; Zandstra, Durk F.

In: Critical Care Medicine, Vol. 37, No. 2, 01.01.2009, p. 545-552.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Citrate anticoagulation for continuous venovenous hemofiltration

AU - Oudemans-Van Straaten, Heleen M.

AU - Bosman, Rob J.

AU - Koopmans, Matty

AU - Van Der Voort, Peter H.J.

AU - Wester, Jos P.J.

AU - Van Der Spoel, Johan I.

AU - Dijksman, Lea M.

AU - Zandstra, Durk F.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - OBJECTIVE:: Continuous venovenous hemofiltration (CVVH) is applied in critically ill patients with acute renal failure for renal replacement. Heparins used to prevent circuit clotting may cause bleeding. Regional anticoagulation with citrate reduces bleeding, but has metabolic risks. The aim was to compare the safety and efficacy of the two. DESIGN:: Randomized, nonblinded, controlled single-center trial. SETTING:: General intensive care unit of a teaching hospital. PATIENTS:: Adult critically ill patients needing CVVH for acute renal failure and without an increased bleeding risk. INTERVENTIONS:: Regional anticoagulation with citrate or systemic anticoagulation with the low-molecular weight heparin nadroparin. MEASUREMENTS AND MAIN RESULTS:: End points were adverse events necessitating discontinuation of study anticoagulant, transfusion, metabolic and clinical outcomes, and circuit survival. Of the 215 randomized patients, 200 received CVVH per protocol (97 citrate and 103 nadroparin). Adverse events required discontinuation of citrate in two patients (accumulation and clotting) of nadroparin in 20 (bleeding and thrombocytopenia) (p < 0.001). Bleeding occurred in 6 vs. 16 patients (p = 0.08). The median number of red blood cell units transfused per CVVH day was 0.27 (interquartile range, 0.0-0.63) for citrate, 0.36 (interquartile range, 0-0.83) for nadroparin (p = 0.31). Citrate conferred less metabolic alkalosis (p = 0.001) and lower plasma calcium (p < 0.001). Circuit survival was similar. Three-month mortality on intention-to-treat was 48% (citrate) and 63% (nadroparin) (p = 0.03), per protocol 45% and 62% (p = 0.02). Citrate reduced mortality in surgical patients (p = 0.007), sepsis (p = 0.01), higher Sepsis-Related Organ Failure Assessment score (p = 0.006), and lower age (p = 0.009). CONCLUSIONS:: The efficacy of citrate and nadroparin anticoagulation for CVVH was similar, however, citrate was safer. Unexpectedly, citrate reduced mortality. Less bleeding could only partly explain this benefit, less clotting could not. Post hoc citrate appeared particularly beneficial after surgery, in sepsis and severe multiple organ failure, suggesting interference with inflammation.

AB - OBJECTIVE:: Continuous venovenous hemofiltration (CVVH) is applied in critically ill patients with acute renal failure for renal replacement. Heparins used to prevent circuit clotting may cause bleeding. Regional anticoagulation with citrate reduces bleeding, but has metabolic risks. The aim was to compare the safety and efficacy of the two. DESIGN:: Randomized, nonblinded, controlled single-center trial. SETTING:: General intensive care unit of a teaching hospital. PATIENTS:: Adult critically ill patients needing CVVH for acute renal failure and without an increased bleeding risk. INTERVENTIONS:: Regional anticoagulation with citrate or systemic anticoagulation with the low-molecular weight heparin nadroparin. MEASUREMENTS AND MAIN RESULTS:: End points were adverse events necessitating discontinuation of study anticoagulant, transfusion, metabolic and clinical outcomes, and circuit survival. Of the 215 randomized patients, 200 received CVVH per protocol (97 citrate and 103 nadroparin). Adverse events required discontinuation of citrate in two patients (accumulation and clotting) of nadroparin in 20 (bleeding and thrombocytopenia) (p < 0.001). Bleeding occurred in 6 vs. 16 patients (p = 0.08). The median number of red blood cell units transfused per CVVH day was 0.27 (interquartile range, 0.0-0.63) for citrate, 0.36 (interquartile range, 0-0.83) for nadroparin (p = 0.31). Citrate conferred less metabolic alkalosis (p = 0.001) and lower plasma calcium (p < 0.001). Circuit survival was similar. Three-month mortality on intention-to-treat was 48% (citrate) and 63% (nadroparin) (p = 0.03), per protocol 45% and 62% (p = 0.02). Citrate reduced mortality in surgical patients (p = 0.007), sepsis (p = 0.01), higher Sepsis-Related Organ Failure Assessment score (p = 0.006), and lower age (p = 0.009). CONCLUSIONS:: The efficacy of citrate and nadroparin anticoagulation for CVVH was similar, however, citrate was safer. Unexpectedly, citrate reduced mortality. Less bleeding could only partly explain this benefit, less clotting could not. Post hoc citrate appeared particularly beneficial after surgery, in sepsis and severe multiple organ failure, suggesting interference with inflammation.

KW - Acute renal failure

KW - Anticoagulation

KW - Citrate

KW - Hemofiltration

KW - Heparin

KW - Nadroparin

KW - Sepsi

UR - http://www.scopus.com/inward/record.url?scp=67649904300&partnerID=8YFLogxK

U2 - 10.1097/CCM.0b013e3181953c5e

DO - 10.1097/CCM.0b013e3181953c5e

M3 - Article

VL - 37

SP - 545

EP - 552

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 2

ER -